Literature DB >> 30443881

Treatment delays from transfers of care and their impact on breast cancer quality measures.

Richard J Bleicher1,2, Cecilia Chang3, Chihsiung E Wang3, Lori J Goldstein4,5, Cary S Kaufmann4,6, Meena S Moran4,7, Karen A Pollitt4,8,9, Nicholas R Suss9,10, David P Winchester4,9,11,12, Lorraine Tafra4,13, Katharine Yao4,12.   

Abstract

PURPOSE: Despite delays between diagnosis and surgery adversely affecting survival, patients frequently transfer their breast cancer care between institutions. This study was performed to assess the prevalence and effect of such transfers of care (TsOC) on the time to surgery, and its impact on current time-dependent breast cancer quality metrics at Commission on Cancer (CoC) and National Accreditation Program for Breast Centers (NAPBC)-accredited institutions.
METHODS: Patients having non-metastatic invasive breast cancer diagnosed between 2006 and 2015 at CoC and NAPBC centers ("reporting facilities") in the National Cancer Database were reviewed. TsOC refer to transferring into or out of a reporting facility between diagnosis and surgery.
RESULTS: Among 622,793 patients, 36.6% of patients transferred care. TsOC add 7.3, 7.8, 8.7, and 9.8 days in time to surgery, chemotherapy, radiotherapy, and endocrine therapy, respectively (p's < 0.0001). On multivariable analysis, the odds of surgery occurring > 90 days from diagnosis were greatest for patients undergoing unilateral or bilateral mastectomy, Black or Hispanic patients, and those having TsOC (ORs > 1.73, p's < 0.0001). TsOC increase the odds of non-compliance, per patient, for chemotherapy, radiotherapy and endocrine therapy time-dependent measures by 65.4%, 25.6%, and 56.5%, respectively (p < 0.0001).
CONCLUSIONS: TsOC for newly diagnosed breast cancers to or from an accredited facility result in delays in time to surgery which can affect compliance with time-dependent quality measures. Facilities frequently receiving transferred patients may be most adversely affected. Although non-compliance with these quality measures is low, institutions and accrediting bodies should be aware of these associations in order to comply with time-dependent standards.

Entities:  

Keywords:  Breast cancer; Delays; Quality measures; Second opinions; Transfers of care

Mesh:

Year:  2018        PMID: 30443881     DOI: 10.1007/s10549-018-5046-x

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Rural-Urban Differences in Breast Cancer Surgical Delays in Medicare Beneficiaries.

Authors:  Ronnie J Zipkin; Andrew Schaefer; Changzhen Wang; Andrew P Loehrer; Nirav S Kapadia; Gabriel A Brooks; Tracy Onega; Fahui Wang; Alistair J O'Malley; Erika L Moen
Journal:  Ann Surg Oncol       Date:  2022-05-24       Impact factor: 4.339

2.  Time to Surgery and the Impact of Delay in the Non-Neoadjuvant Setting on Triple-Negative Breast Cancers and Other Phenotypes.

Authors:  Alina M Mateo; Anna M Mazor; Elias Obeid; John M Daly; Elin R Sigurdson; Elizabeth A Handorf; Lyudmila DeMora; Allison A Aggon; Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2019-11-11       Impact factor: 5.344

3.  Variations in breast cancer surgical treatment and timing: determinants and disparities.

Authors:  Irene Dankwa-Mullan; Judy George; M Christopher Roebuck; Joseph Tkacz; Van C Willis; Fredy Reyes; Yull E Arriaga
Journal:  Breast Cancer Res Treat       Date:  2021-03-10       Impact factor: 4.872

4.  Association between initiation of adjuvant chemotherapy beyond 30 days after surgery and overall survival among patients with triple-negative breast cancer.

Authors:  Erik Heeg; Perla J Marang-van de Mheen; Marissa C Van Maaren; Kay Schreuder; Rob A E M Tollenaar; Sabine Siesling; Monique E M M Bos; Marie-Jeanne T F D Vrancken Peeters
Journal:  Int J Cancer       Date:  2019-11-28       Impact factor: 7.396

5.  Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer.

Authors:  William H Ward; Lyudmila DeMora; Elizabeth Handorf; Elin R Sigurdson; Eric A Ross; John M Daly; Allison A Aggon; Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2019-09-27       Impact factor: 5.344

6.  Covid-19 related oncologist's concerns about breast cancer treatment delays and physician well-being (the CROWN study).

Authors:  Katharine A Yao; Deanna Attai; Richard Bleicher; Kristine Kuchta; Meena Moran; Judy Boughey; Lee G Wilke; Jill R Dietz; Randy Stevens; Catherine Pesce; Katherine Kopkash; Scott Kurtzman; Terry Sarantou; David Victorson
Journal:  Breast Cancer Res Treat       Date:  2021-01-31       Impact factor: 4.872

Review 7.  The Relationship between Time to Surgery (TTS) and Survival in Breast Cancer: A Systematic Review and Meta-Analysis.

Authors:  Yongcheng Su; Xiaogang Zheng; Zhong Ouyang
Journal:  Iran J Public Health       Date:  2021-09       Impact factor: 1.429

8.  Treatment times in breast cancer patients receiving neoadjuvant vs adjuvant chemotherapy: Is efficiency a benefit of preoperative chemotherapy?

Authors:  Nicole M Melchior; Darren B Sachs; Gabrielle Gauvin; Cecilia Chang; Chihsiung E Wang; Elin R Sigurdson; John M Daly; Allison A Aggon; Shelly B Hayes; Elias I Obeid; Richard J Bleicher
Journal:  Cancer Med       Date:  2020-02-25       Impact factor: 4.452

9.  Nationwide population-based study of the impact of immediate breast reconstruction after mastectomy on the timing of adjuvant chemotherapy.

Authors:  E Heeg; J X Harmeling; B E Becherer; P J Marang-van de Mheen; M T F D Vrancken Peeters; M A M Mureau
Journal:  Br J Surg       Date:  2019-08-06       Impact factor: 6.939

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.